Han Zhe, Chi Huizhong, Li Xueen, Jia Deze, Li Haiyan, Ni Shilei, Zhang Kailiang, Feng Zichao, Wang Qingtong, Xue Hao, Li Gang
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, Shandong, China.
Front Neurosci. 2023 Apr 13;17:1158601. doi: 10.3389/fnins.2023.1158601. eCollection 2023.
The emergence of the new WHO classification standard in 2021 incorporated molecular characteristics into the diagnosis system for meningiomas, making the diagnosis and treatment of meningiomas enter the molecular era.
At present, there are still some problems in the clinical molecular detection of meningioma, such as low attention, excessive detection, and a long cycle. In order to solve these clinical problems, we realized the intraoperative molecular diagnosis of meningioma by combining real-time fluorescence PCR and AIGS, which is also the first known product applied to the intraoperative molecular diagnosis of meningioma.
We applied AIGS to detect and track a patient with TERTp mutant meningioma, summarized the process of intraoperative molecular diagnosis, and expounded the significance of intraoperative molecular diagnosis under the new classification standard, hoping to optimize the clinical decision-making of meningioma through the diagnosis and treatment plan of this case.
2021年世界卫生组织新分类标准的出现将分子特征纳入脑膜瘤诊断系统，使脑膜瘤的诊断和治疗进入分子时代。
目前，脑膜瘤临床分子检测仍存在一些问题，如重视程度不够、检测过度、周期长等。为解决这些临床问题，我们通过实时荧光定量聚合酶链反应（PCR）与人工智能基因组测序（AIGS）相结合实现了脑膜瘤术中分子诊断，这也是已知首个应用于脑膜瘤术中分子诊断的产品。
我们应用AIGS检测并追踪1例端粒酶逆转录酶启动子（TERTp）突变型脑膜瘤患者，总结术中分子诊断过程，并阐述新分类标准下术中分子诊断的意义，希望通过该病例的诊疗方案优化脑膜瘤的临床决策。
